The firm proactively collaborates with founders, fund managers, and LPs across the venture lifecycle—from inception through exit. With investments in over 425 venture funds and 325 companies, we take a data-driven approach to investing in leading venture funds and companies through both primary and secondary transactions.
We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas, including oncology, immunology, rare diseases, precision medicine and others.
A unified approach for access to the best complete venture lifecycle with comple mentary risk, reward, and liquidity profiles.
We limited partnership interests in venture capital funds, facilitate special situation investments, and directly purchase shares in mature and pre-IPO businesses through secondary transactions. Our flexibility and creativity enables us to structure a solution for the most straightforward to the most complicated parameters.
Guto is Proudly Powered by GutoTheme
